Skip to main content

Response to Comment on “The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis”

The Original Article was published on 01 November 2022

Dear authors,

Thank you for reading our paper and for the critical analysis. All suggestions are relevant, and the issues were deeply discussed by our group to solve them.

About the first point raised by the authors, we agreed that we had lesser papers about anti-TNF therapy included. However, we revised our inclusion/exclusion criteria, and we decided to still not include the mentioned papers. These studies presented relevant data, but methodological issues such as therapy regimen force us to exclude them.

The second point, about why we did not perform our analysis with the valued adjusted by size, is relevant and must be discussed. The main problem is because not all studies collected or mentioned that data, so the number of studies in the meta-analysis would significantly decrease. Still, we agreed that adjusted muscle mass and not adjusted muscle mass are different measures, and we are planning to perform this analysis to add in a possible reply to this letter.

Finally, with the last point, we agreed that DEXA and BIA are different methods of body composition measure and that could lead to confusion in results. Our group decided to perform another meta-analysis separating studies that used DEXA from studies that used BIA and add that data in a reply to this letter.

Author information

Authors and Affiliations

Authors

Contributions

The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Thales R. Hein.

Ethics declarations

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hein, T.R., Peterson, L., Bartikoski, B.J. et al. Response to Comment on “The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis”. Arthritis Res Ther 24, 246 (2022). https://doi.org/10.1186/s13075-022-02932-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13075-022-02932-5